From the infectious diseases society of America: Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever

Journal of Infectious Diseases

Volumn 161, Issue 3, 1990, Pages 381-396

  Hughes, Walter T ^a   Armstrong, Donald ^a   Bodey, Gerald P ^a   Feld, Ronald ^a   Mandell, Gerald L ^a   Meyers, Joel D ^a   Pizzo, Philip A ^a   Schimpff, Stephen C ^a   Shenep, Jerry L ^a   Wade, James C ^a   Young, Lowell S ^a   Yow, Martha D ^a  

^a Infect Diseases Society of America   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI INFECTIVE AGENTS; ANTIINFECTIVE AGENT; ACICLOVIR; AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; AZLOCILLIN; CEFALOTIN; CEFOPERAZONE; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLAVULANIC ACID; COLISTIN; FRAMYCETIN; GENTAMICIN; MEZLOCILLIN; NYSTATIN; PENICILLIN DERIVATIVE; PIPERACILLIN; POLYMYXIN B; QUINOLONE DERIVATIVE; SULFAMETHOXAZOLE; TICARCILLIN; TOBRAMYCIN; TRIMETHOPRIM; VANCOMYCIN;

AGRANULOCYTOSIS; BACTERIAL INFECTION; CONFERENCE PAPER; HUMAN; MYCOSIS; NEUTROPENIA; PRACTICE GUIDELINE; PYREXIA IDIOPATHICA; ANTIBIOTIC PROPHYLAXIS; BACTEREMIA; BACTERIUM CULTURE; DISEASE COURSE; DRUG CHOICE; DRUG EFFICACY; DRUG POTENTIATION; FEVER; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GRANULOCYTE TRANSFUSION; INTRAVASCULAR CATHETER; PRESCRIPTION; PRIORITY JOURNAL; REVIEW;

AGRANULOCYTOSIS; ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; FEVER OF UNKNOWN ORIGIN; HUMAN; MYCOSES; NEUTROPENIA;

EID: 0025236663     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/161.3.381     Document Type: Article

References (176)

1. Bodey G.P., Buckley M., Sathe Y.S., Freireich E.J. Quantitative relationships between circulating leukocytes and infections in patients with acute leukemia. Ann Intern Med 1966;64:328–340
2. Schimpff S.C. Empiric antibiotic therapy for granulocytopenic cancer patients. Am J Med 1986;80(suppl 5C):13–20
3. Bustamante C.L., Newman K.A., Devlin A., Wade J.C. Changing patterns of infection in patients with cancer [abstract]. Proceedings of the annua] meeting of the American Society for Microbiology, Miami, 1988
4. Dale D.C., Guerry D., Wewerka I.V. Jr, Bull J.M., Chusid MJ. Chronic neutropenia. Medicine 1979;58:128–144
5. Whimbey E., Wong B., Kiehn T.E., Armstrong D. Clinical correlations of serial quantitative blood cultures determined by lysis-centrifugationin patients with persistent septicemia. J Clin Microbioi 1984;19: 766–771
6. Flynn P.M., Van Hooser B., Gigliotti F. Atypical mycobacterial infections of Hickman catheter exit sites. Pediatr Infect Dis 1988;7:510–513
7. Brown E.A., Talbot G.H., Provencher M., Cassileth P. Anaerobic bacteremia in patients with acute leukemia. Infect Control Hosp Epidemiol 1989;10:65–69
8. Allen V., Smith C.R., Probes C.G. The value of skin biopsies in febrile, neutropenic, immunocompromised children. Am J Dis Child 1986; 140:459–461
9. Fainstein V., Bodey G.P., McCredie K.B., Keating M.J., Estey E.H., Bolivar R., Elting L. Coagulation abnormalities induced by /3-lactam antibiotics in cancer patients. J Infect Dis 1983;148;745–750
10. Conly J.M., Chubb H., Bow E.J., Louie T.J. Hypoprothrombinemia in febrile neutropenic patients with cancer: Association with antimicrobial suppression of intestinal microflora. J Infect Dis 1984;150:202–212
11. Press O.W., Ramsey P.G., Larson E.B., Hefer A., Hickman R.D. Hickman catheter infections in patients with malignancies. Medicine 1984; 63:189–200
12. Benezra D., Kiehn T.E., Gold J.W.M., Brown A.E., Turnbull A.D.M., Armstrong D. Prospective study of infection in indwelling central venous catheters using quantitative blood cultures. Am J Med 1988;85: 495–498
13. Pater J.L., Weir L. Reporting the results of randomized trials of empiric antibiotics in febrile neutropenic patients-a critical survey. J Clin Oncol 1986;4:346–352
14. Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient: report of a consensus panel for the Immunocompromised Host Society. J Infect Dis 1990;161:397–401
15. Klastersky J., Vamecq G., Cappel R., Swings G., Vandenboure L. Effects of the combination of gentamicin and carbenicillin on the bactericidal activity of serum. J Infect Dis 1972;125:183–186
16. Bodey G.P., Jadeja L., Elting L. Pseudomonas bacteremia: retrospective analysis of 410 episodes. Arch Intern Med 1985;145:1621–1629
17. EORTC International Antimicrobial Therapy Project Group. Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. J Infect Dis 1978;137:14–29
18. De Jongh C.A., Joshi J.H., Thompson B.W., Newman K.A., Finley R.S., Moody M.R., Salvatore P.C., Tenney J.H., Drusano G.L., Schimpff S.C. A double beta-lactam combination versus an aminoglycoside-containing regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients. Am J Med 1986;80:101–111
19. Winston D.J., Winston G.H., Bruckner D.A., Gale R.P., Champlin R.E. Controlled trials of double beta-lactam therapy with cefoperazone plus piperacillin in febrile granulocytopenic patients. Am J Med 1988; 85(suppl 1A): 21–30
20. Mortimer J., Miller S., Black D., Kwok K., Kirby W.M. Comparison of cefoperazone and mezlocillin with imipenem as empiric therapy in febrile neutropenic cancer patients. Am J Med 1988;85(suppl 1A): 17–20
21. Anaissie E.J., Fainstein V., Bodey G.P., Rolston K., Elting L., Kantarjian H., Cabanillas F., McCredie K.B. Randomized trial of beta-lactam regimens in febrile neutropenic cancer patients. Am J Med 1988; 84:581–589
22. Winston D.J., Barner R.C., Ho W.G., Ybung L.S., Champion R.E., Gale R.P. Moxalactam plus piperacillin versus moxalactam plus amikacin in febrile granulocytopenic patients. Am J Med 1984;77:442–450
23. Fainstein V., Bodey G.P., Boliva R., Elting L., McCredie K.B., Keating M.J. Moxalactam plus ticarcillin or tobramycin for treatment of febrile episodes in neutropenic cancer patients. Arch Intern Med 1984;144:1776–1780
24. Rotstein C., Cimino M., Winkey K., Cesari C., Fenner J. Cefoperazone plus piperacillin versus mezlocillin plus tobramycin as empiric therapy for febrile episodes in neutropenic patients. Am J Med 1988;85(suppl 1A): 36–39
25. Gutmann L., Williamson R., Kitzic M.D., Acar J.F. Synergism and antagonism in double beta-lactam antibiotic combinations. Am J Med 1986;80(suppl 5C):21–29
26. Donowitz G.R., Mandell G.L. Beta-lactam antibiotics. Part I. N Engl J Med 1988;318:419–426
27. Donowitz G.R., Mandell G.L. Beta-lactam antibiotics. Part II. N Engl J Med 1988;318:490–500
28. Pizzo P.A., Hathom J.W., Hiemenz J., Brown M., Cotton D., Gress J., Longo D., Marshall D., McKnight J., Rubin M., Skelton J., Thaler M., Wesley R.A. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986;315:552–558
29. Verhagen C.S., de Pauw B., de Witte T., Janssen J., Williams K., de Mulder P., Bothof T. Randomized prospective study of ceftazidime versus ceftazidime plus cephalothin in empiric treatment of febrile episodes in severely neutropenic patients. Antimicrob Agents Chemother 1987;31:191–196
30. Wade J.C., Johnson D.E., Bustamante C.l. Monotherapy for empiric treatment of fever in granulocytopenic cancer patients. Am J Med 1986; 80(suppl 5C):85–95
31. EORTC International Antimicrobial Therapy Cooperative Group. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med 1987;317:1692–1698
32. Ramphal R., Kramer B.S., Rand K.H., Weiner R.S., Shands J.W. Jr. Early results of a comparative trial of ceftazidime versus cephalothin, carbenicillin and gentamicin in the treatment of febrile granulocytopenic patients. J Antimicrob Chemother 1983;12(suppl A):81–88
33. Rubin M., Hathorn J.W., Marshall D., Gress J., Steinberg S.M., Pizzo P.A. Gram-positive infections and the use of vancomycin in episodes of fever and neutropenia. Ann Intern Med 1988;108:30–35
34. Schwalbe R.S., Stapleton J.T., Gilligan P.H. Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med 1987; 316:927–931
35. Shenep J., Hughes W.T., Roberson P.K., Blankenship K., Baker D., Meyer W.H., Gigliotti F., Sixbey J.W., Santana V.M., Feldman S., Lott L. Vancomycin, ticarcillin and amikacin compared with ticarcillin- clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer. N Engl J Med 1988;319:1053–1058
36. Karp J.E., Hick J.D., Angelopulos C., Charache P., Green L., Burke P.J., Saral R. Empiric use of vancomycin during prolonged treatment- induced granulocytopenia. Am J Med 1986;81:237–242
37. Kramer B.S., Ramphal R., Rand K.H. Randomized comparison between two ceftazidime-containing regimens and cephalothin-gentamicin- carbenicillin in febrile granulocytopenic cancer patients. Antimicrob Agents Chemother 1986;30:64–68
38. Granowetten L., Wells H., Lange B.J. Ceftazidime with or without vancomycin vs. cephalothin, carbenicillin and gentamicin as initial therapy of the febrile neutropenic pediatric cancer patient. Pediatr Infect Dis J 1988;7:165–170
39. EORTC Antimicrob Therapy Cooperative Group. Ceftazidime plus amikacin with or without vancomycin as empirical therapy of fever in cancer patients with granulocytopenia [abstract 18], In: Proceedings of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, 1988
40. Pizzo P.A., Ladisch S., Robichaud K. Treatment of gram-positive septicemia in cancer patients. Cancer 1980;45:206–207
41. Wilson R., Feldman S. Toxicity of amphotericin B in children with cancer. Am J Dis Child 1979;133:731–734
42. Churchill D.N., Seely J. Nephrotoxicity associated with combined gentamicin-amphotericin B therapy. Nephron 1977;19:176–181
43. Pizzo P.A., Robichaud K.J., Gill F.A., Witebsky F.G. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982;72:101–111
44. Pizzo P.A., Robichaud K.J., Gill F.A., Witebsky F.G., Levine A.S., Deisscroth A.B., Glaubiger D.L., MacLowery J.D., Magrath I.T., Foplack D.A., Siman R.M. Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. Am J Med 1979;67:194–200
45. Hughes W.T., Patterson G. Post-sepsis prophylaxis in cancer patients. Cancer 1984;53:137–141
46. Joshi J.H., Schimpff S.C., Tenney J.H., Newman K.A., DeJongh C.A. Canantibacterial therapy be discontinued in persistently febrile granulocytopenic cancer patients? Am J Med 1984;76:450–457
47. Bartley D.L., Hughes W.T., Parvey L.S., Parham D. Computed tomography of hepatic and splenic fungal abscesses in leukemic children. Pediatr Infect Dis 1982;1:317–321
48. Talbot G.H., Provencher M., Cassileth P.A. Persistent fever after recovery from granulocytopenia in acute leukemia. Arch Intern Med 1988;148:129–135
49. Clasener H.A.L., Vollaard E.J., van Saene H.K.F. Long-term prophylaxis of infection by selective decontamination in leukopenia and in mechanical ventilation. Rev Infect Dis 1987;9:295–328
50. Van der Waaij D. Colonization resistance of the digestive tract as a major lead in the selection of antibiotics for therapy. In: Van der Waaij Verhoef J, eds. New criteria for antimicrobial therapy. Amsterdam: Excerpta Medica, 1979:271
51. Hughes W.T., Kuhn S., Chaudhary S., Feldman S., Verzosa M., Aur R.J.A., Pratt C., George S.L. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1977;297:1419–1426
52. Karp J.E., Merz W.G., Hendricksen C., Laughon B., Redden T., Bamberger B.J., Bartlett J.G., Saral R., Burke P.J. Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. Ann Intern Med 1987;106:1–7
53. Winston D.J., Winston G.H., Nakao S.L., Gale R.P., Champlin R.E. Norfloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. Am J Med 1986;80:884–889
54. Bow E.J., Rayner E., Louie T.J. Comparison of norfloxacin with cotrimazole for infectious prophylaxis in acute leukemia. Am J Med 1988;84:847–854
55. Dekker A., Rozenberg-Arska M., Verhoef J. Infection prophylaxis in acute leukemia: A comparison of ciprofloxacin with trimethoprim- sulfamethoxazole and colistin. Ann Intern Med 1987;106:7–12
56. Denning D., Fulle H.H., Hellriegel K.P. Chemoprophylaxis of bacterial infection in granulocytopenic patients with ciprofloxacin. Onkologie 1987;10:57–58
57. EORTC International Antimicrobial Therapy Cooperative Group. Combination of amikacin and carbenicillin with or without cefazolin as empiric treatment of febrile neutropenic patients. J Clin Oncol 1983; 1:597–603
58. Winston D.J., Ho W.G., Young L.S., Hewitt W.L., Gale R.P. Piperacillin plus amikacin therapy v. carbenicillin plus amikacin therapy in febrile granulocytopenic patients. Arch Intern Med 1982;142:1663–1667
59. Lau W.K., Young L.S., Black R.E., Winston D.J., Linne S.R., Weinstein R.J., Hewitt W.L. Comparative efficacy and toxicity of amikacin/carbeni- cillin versus gentamicin/carbenicillin in leukopenic patients. Am J Med 1977;62:959–965
60. Keating M.J., Bodey P.G., Valdivieso M., Rodriguez V. A randomized comparative trial of three aminoglycosides-comparison of continuous infusions of gentamicin, amikacin and sisomicin combined with carbenicillin in the treatment of infections in neutropenic patients with malignancies. Medicine 1979;68:159–170
61. Femandez-Ranada J., Femandez-Garese D., Caretti D., Vazquez L., Escudero A., Olmeda F. Empiric antibiotic therapy with an amikacin- carbenicillin-cefoxitin combination in granulocytopenic febrile patientsa clinical report. Int J Clin Pharmacol Ther Toxicol 1983; 21:511–513
62. Cortelezzi A., Radaelli F., Penagini R., Pagliani E.M. Empiric treatment of infections in granulocytopenic patients with acute leukemia: A study on amikacin-carbenicillin-cotrimoxazole. Int J Clin Pharmacol Ther Toxicol 1982;20:520–523
63. Wade J.C., Schimpff S.C., Newman K.A., Fortner C.l., Standiford H.C., Wiernik P.H. Piperacillin of ticarcillin plus amikacin. A double-blind prospective comparison of empiric antibiotic therapy for febrile or granulocytopenic cancer patients. Am J Med 1981;71:983–990
64. Finley R.S., Fortner C.L., de Jongh C.A., Wade J.C., Newman K.A., Caplan Britten J., Wiernik P.H., Schimpff S.C. Comparison of standard versus pharmacokinetically adjusted amikacin dosing in granulocytopenic cancer patients. Antimicrob Agents Chemother 1982;22: 193–197
65. Klastersky J., Glauser M.P., Schimpff S.C., Zinner S.H., Gaya H. Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients. Antimicrob Agents Chemother 1986;29:263–270
66. Love U., Schimpff S.C., Hahn D.M., Young V.M., Standiford H.C., Bender J.F., Fortner C.L., Wiernik P.H. Randomized trial of empiric antibiotic therapy with ticarcillin in combination with gentamicin, amikacin, or netilmicin in febrile patients with granulocytopenia and cancer. Am J Med 1979;66:603–610
67. Bru J.P., Michallet M., Legrand C., Swierz P., Stahl J.P., Leautet J.B., Sotto J.J., Holland D., Micoud M. A prospective randomized study comparing the efficacy of timentin alone or in combination with amikacin in the treatment of febrile neutropenic patients. J Antimicrob Chemother 1986;17(suppl C):203–209
68. Meunier F., Snoeck R., Lagast H., Woussen F., Klastersky J. Empirical antimicrobial therapy with timentin plus amikacin in febrile granulocytopenic cancer patients. J Antimicrob Chemother 1986;17(suppl C): 195–201
69. de Jongh C.A., Wade J.C., Schimpff S.C., Newman K.A., Finley R.S., Salvatore P.C., Moody M.R., Standiford H.C., Fortner C.L., Wiernik P.H. Empiric antibiotic therapy for suspected infection in granulocytopenic cancer patients: A comparison between the combination of moxa- lactam plus amikacin and ticarcillin plus amikacin. Am J Med 1982;73:89–96
70. Casali A., Ameglio F., Gionfra T., Tonachella R., Paoletti G., Gallo C. Amikacin plus ceftazidime versus amikacin plus piperacillin versus amikacin plus aztreonam in infections in neoplastic patients with granulocytopenia. Chemotherapia 1987;6:440–444
71. Menichetti F., Del Favero A., Guerciolini R., Tonato M., Aversa F., Roila Frongillo R.F., Martelli M.F., Davis S., Pauluzzi S. Empiric antimicrobial therapy in febrile granulocytopenic patients. Randomized prospective comparison of amikacin plus piperacillin with or without parenteral trimethoprim-sulfamethoxazole. Infection 1986;14: 261–267
72. Sampi K., Kumai R., Maseki N., Sakurai M., Kaneko Y., Hattori M. Cefmenoxime or piperacillin plus amikacin. A prospective randomized comparison of empiric antibiotic therapy of febrile granulocytopenic cancer patients. Gan To Kagaku Ryoho 1987;14:674–679
73. Sampi K., Kumai R., Sakurai M., Kaneko Y., Hattori M. Empiric therapy with piperacillin plus amikacin for febrile patients with cancer- with emphasis on granulocytopenia. Gan To Kagaku Ryoho 1985;12:1301–1305
74. Klastersky J., Glauser M.P., Schimpff S.C., Zinner S.H., Gaya H. Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients. Antimicrob Agents Chemother 1986;29:263–270
75. Sampi K., Honda T., Hattori M. Sulbenicillin and amikacin for febrile patients with cancer-with special reference to granulocytopenia. Gan To Kagaku Ryoho 1983;10:2377–2381
76. Palmblad J., Lonnquist B. Combination of amikacin and either ampicillin or cephalothin as initial treatment of febrile neutropenic patients. Acta Med Scand 1982;212:379–384
77. Vannier J.P., Gardembas-Pain M., Blaysat G., Lemeland J.F., Tron P. Comparison of two versus three daily infusions of cefotaxime plus amikacin in granulocytopenic children. Drugs 1988;35(suppl 2):231
78. parison of two versus three daily infusions of cefotaxime plus amikacin in granulocytopenic children. Drugs 1988;35(suppl 2):231
79. Martino P., Venditti M., Petti M.C., Mandelli F., Serra P. Cefotaxime plus amikacin as empiric therapy in the treatment of febrile episodes in neutropenic patients with hematologic malignancies. Infection 1985;13:125–129
80. Santi G., Carella A.M., Bacigalupo A., van Lint M.T., Congiu A.M., Occhini D., Costa G., Shaff A., Accornero L., Sciutto C. Cefoperazone versus cefotaxime plus amikacin or sisomicin, in fever and infection in haematologic granulocytopenic patients. Tumori 1984; 70:151–158
81. Piccart M., Klastersky J., Meunier F., Lagast H., van Laethem Y., Weerts D. Single-drug versus combination empirical therapy for gram- negative bacillary infection in febrile cancer patients with and without granulocytopenia. Antimicrob Agents Chemother 1984;26: 870–875
82. Jones P.G., Rolston K.V., Fainstein V., Elting L., Walters R.S., Bodey G.P. Aztreonam therapy in neutropenic patients with cancer. Am J Med 1986;81:243–248
83. Jones P., Raison K., Fainstein V., Elting L., Bodey G.P. Aztreonam plus vancomycin (plus amikacin) vs. moxalactam plus ticarcillin for the empiric treatment of febrile episodes in neutropenic cancer patients. Rev Infect Dis 1985;7(suppl 4):S741–S746
84. Bodey G.P., Middleman E., Umsawasdi T., Rodriguez V. Infections in cancer patients-results with gentamicin sulfate therapy. Cancer 1972;29:1697–1701
85. Bodey G.P., Feld R., Burgess M.A. Beta-lactam antibiotics alone or in combination with gentamicin for therapy of gram-negative bacillary infections in neutropenic patients. Am J Med Sci 1976;271:179–186
86. Stuart R.K., Braine H.G., Lietman P.S., Saral R., Fuller D.J. Carbenicillintrimethoprim-sulfamethoxazole versus carbenicillin-gentamicin as empiric therapy of infection in granulocytopenic patients. A prospective randomized double-blind study. Am J Med 1980;68:876–885
87. Schimpff S.C., Satterlee W., Young V.M., Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 1971;284:1061–1065
88. Bjornsson B., Preisler H., Henderson E.S. A study of antibiotic therapy in fever of unknown origin in neutropenic cancer patients. Pediatr Oncol 1977;3:379–385
89. Pizzo P.A, Hathom J.W., Hiemenz J., Browne M., Commers J., Cotton D., Gress J., Longo D., Marshall D., McKnight J., Rubin M., Skelton J., Thaler M., Wesley R. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986;315:552–558
90. Commers J.R., Gress J.G., Robichaud K.J., Longo D.L., Pizzo P.A. Keflin, gentamicin, carbenicillin vs ceftazidime as empiric therapy for febrile granulocytopenic cancer patients [abstract 2]. In: Proceedings of the 22nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Miami Beach, 1982
91. Nachman J.B., Honig G.R. Fever and neutropenia in children with neoplastic disease: An analysis of 158 episodes. Cancer 1980;45:407–412
92. Bloomfield C.D., Kennedy B.J. Cephalothin, carbenicillin and gentamicin combination therapy for febrile patients with non-lymphocytic leukemia. Cancer 1974;34:431–437
93. Halpem J., Catane R., Sacks T., Fuks Z. Treatment of febrile granulocytopenic cancer patients receiving antineoplastic therapy with a combination of carbenicillin, cefazolin and gentamicin. J Med Clin Exp Theor 1983;14:193–202
94. Gurwith M., Brunton J.L., Lank B., Ronald A.R., Herding G.K., McCullough D.W. Granulocytopenia in hospitalized patients. II. A prospective comparison of two antibiotic regimens in the empiric therapy of febrile patients. Am J Med 1978;64:127–132
95. Schimpff S.C., Landesman S., Hahn D.M., Standiford H.C., Fortner C.L., Young V.M., Wiemick P.H. Ticarcillin in combination with cephalothin or gentamicin as empiric antibiotic therapy in granulocytopenic cancer patients. Antimicrob Agents Chemother 1976;10:837–844
96. Gonzales M., Clavell L.A. Piperacillin and gentamicin as non-toxic empirical therapy in pediatric patients with fever and neutropenia. Pub Health Sci J 1987;6:13–15
97. O’Brien A.J., Fenelon L.E., O’Dwyer R., McCann S.R., Daly P.A. A comparative study of latamoxef disodium and gentamicin versus piperacillin and gentamicin in febrile granulocytopenic patients. Br J Clin Pract 1988;42:56–60
98. Valdivieso M., Bodey G.P., Burgess M.A., Rodriguez V. Therapy of infections in neutropenic patients: results with gentamicin in combination with cephalothin or chloramphenicol. Med Pediatr Oncol 1976;2:99–108
99. de Pauw B.E., Kauw F., Muytjens H., Williams K.J., Bothof T. Randomized study of ceftazidime versus gentamicin plus cefotaxime for infections in severe granulocytopenic patients. J Antimicrob Chemother 1983;12(suppl 12A):93–99
100. Chambers S.K., Schwartz P.E. Neutropenia and fever in patients undergoing combination chemotherapy for malignant germ cell tumors of the ovary. Obstet Gynecol 1986;68:842–846
101. Bodey G.P., Ketchel S.J., Rodriguez V. A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am J Med 1979;67:608–616
102. Lawson R.D., Gentry L.O., Bodey G.P., Keating M.J., Smith T.L. Randomized study of tobramycin plus ticarcillin, tobramycin plus cephalothin and ticarcillin, or tobramycin plus mezlocillin in the treatment of infection in neutropenic patients with malignancies. Am J Med Sci 1984;287:16–23
103. Feld R., Louie T.J., Mandell L., Bow E.J., Robson H.G., Chow A., Belch Miedzinski L., Rachlis A., Pater J. A multicenter comparative trial of tobramycin and ticarcillin vs moxolactam and ticarcillin in febrile neutropenic patients. Arch Intern Med 1985;145:1083–1088
104. Newell P., Noiden C., Ruben F.L., Wing E.J. Tobramycin and ticarcillin as empiric therapy for febrile patients with granulocytopenia: A reevaluation. South Med J 1987;80:836–840
105. Gucalp R., Lisa S., McKitrick J.C., Wiemik P.H. Cefoperazone plus tobramycin versus ticarcillin plus tobramycin in febrile granulocytopenic cancer patients. Am J Med 1988;85:31–35
106. Reilly J.T., Brada M., Bellingham A.J., Hart C.A., Bennet C. Ceftazidime compared to tobramycin and ticarcillin in immunocompromised hae- matological patients. J Antimicrob Chemother 1983;12(suppl A): 89–92
107. Brown A.E., Quesada O., Murrer J.A., Eason J.V., Clarkson B., Armstrong D. Empiric combination antibiotic therapy of febrile, neutropenic patients with neoplastic disease: results of a randomized study. In: Proceedings of the 13th International Congress on Chemotherapy, Vienna, 1983
108. Mackie M.J., Reilly J.T., Purchit S., Bartzokas C.A. A randomized trial of timentin and tobramycin versus piperacillin and tobramycin in febrile neutropenic patients. J Antimicrob Chemother 1986;17(suppl C): 219–224
109. Kreiger O., Bernhart M., Plohowich R., Nemec H., Lutz D. Timentin in combination with tobramycin as empirical therapy in febrile neutropenic patients with haematological malignancies. J Antimicrob Chemother 1986;17(suppl C):211–217
110. Williams M.E., Harman C., Scheld M., Hess C.E., Donowitz G.R. A controlled study of ticarcillin plus clavulanic acid versus piperacillin as empiric therapy for fever in the immunocompromised host. Am J Med 1985;79(suppl 5B):67–72
111. Langley J., Gold R. Sepsis in febrile neutropenic children with cancer. Pediatr Infect Dis J 1988;7:34–37
112. Lowenbraun S., Fox N., Cunitz D. Azlocillin, cephalothin and tobramycin therapy in febrile solid tumor patients with chemotherapy-induced leukopenia. Cancer 1987;60:14–17
113. Hellriegel K.P., Kindler J., Whittenberg C., Kress M. Empiric antibiotic treatment of infections in myelosuppressed cancer patients. Preliminary results. Infection 1982;10(suppl 3):138–140
114. Feld R., Rachlia A., Tuffnell P.G., Duncan I., Moran L., Pinfold P., De Boer G. Empiric therapy for infections in patients with granulocytopenia.Continuous versus interrupted infusion of tobramycin plus cefamandole. Arch Intern Med 1984;144:1005–1010
115. Boer G. Empiric therapy for infections in patients with granulocytopenia. Continuous versus interrupted infusion of tobramycin plus cefamandole. Arch Intern Med 1984;144:1005–1010
116. Papayannis A.G., Thomopoulos D., Voulgaris E., Scliras P., Gardikas C. Tobramycin-cephalothin treatment in leukemia and neutropenic patients with severe infection. J Antimicrob Chemother 1977;3:311–315
117. Cohen J.D., Miaie T.D. Parenteral tobramycin and cephalothin in the treatment of suspected sepsis in neutropenic children. In: Williams J.D., Geddes A.M., eds. Chemotherapy. Vol 1. New York: Plenum Press, 1976:117–122
118. Hjorth M., Weinfeld A., Brorson J.E. Empiric treatment of fever in acute leukemia with tobramycin-cephalothin and the escape clause provision of corticosteroids. Scand J Infect Dis 1980;12:139–148
119. Bezwoda W.R., Derman D.P., Perkins S., Cassel R. Treatment of neutropenic infection: A randomized trial comparing latamoxef (moxalac- tam) with cephradine plus tobramycin. J Antimicrob Chemother 1985;15:239–245
120. Fainstein V., Bodey G.P., Elting L., Bolivar R., Keating M.J., McCredie K.B., Valdivieso M. A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients. J Antimicrob Chemother 1983;12(suppl A):101–110
121. Rhodes E.G., Harris R.I., Welch R.S., Perry D.J., Brown R.N., Boughton B.J. Empirical treatment of febrile, neutropenic patients with tobramycin and latamoxef. J Hosp Infect 1987;9:278–284
122. Alanis A., Rehm S., Weinstein A.J. Comparative efficacy and toxicity of moxalactam and the combination of nafcillin and tobramycin in febrile granulocytopenic patients. Cleve Clin J Med 1983;50:385–395
123. Brunet F., Lanore J.J., Dhainaut J.F., Dreyfus F., Huyghebaert M.F., Varet Monsallier J.F. Efficacy of a combination of cefotaxime, tobramycin and vancomycin as antibiotic therapy for neutropenia. Drugs 1988;35(suppl 2):195
124. Sage R., Hann I., Prentice H.G., Devereux S., Corringham R., Hoffbrand A.V., Blacklock H., Stirling L., Guimaraes M., Trikka E. A randomized trial of empirical antibiotic therapy with one of four beta-lactam antibiotics in combination with netilmicin in febrile neutropenic patients. J Antimicrob Chemother 1988;22:237–247
125. Donnelly J.P., Marcus R.E., Goldman J.M., Cohen J., Worsley A.M., Catovsky D., Darrell J.H., Want S.V., Galton D.A. Ceftazidime as first-line therapy for fever in acute leukaemia. J Infect 1985;11:205–215
126. Schaison G., Reinert P., Leverger G., Leaute J.B. Timentin (ticarcillin and clavulanic acid) in combination with aminoglycosides in the treatment of febrile episodes in neutropenic children. J Antimicrob Chemother 1986;17(suppl C):177–181
127. Leverger G., Demeocq F., Harousseau J.L., Taboureau O., Vannier J.P., Boilletot A., deLumley L., Boutard P., Olive D., Reinert P. TYeatment of febrile episodes in neutropenic children by ceftazidime combined with netilmicin. Results of a multicenter study apropos of 88 cases. Pathol Biol 1987;35:648–651
128. Friis H.S., Hoffman M.M., Hansen T., Justesen T., Nissen N.I. Cefotaxime versus ampicillin, methicillin, and netilmicin in combination for treatment of febrile episodes in patients with haematologic malignancy. Acta Med Scand 1983;213:349–354
129. Middleman E.A., Watanabe A., Kaiser H., Bodey G.P. Antibiotic combinations for infections in neutropenic patients. Evaluation of carbenicil- lin plus either cephalothin or kanamycin. Cancer 1972;30:573–580
130. Keating M.J., Lawson R., Grose W., Bodey G.P. Combination therapy with ticarcillin and sulfamethoxazole-trimethoprim for infections in patients with cancer. Arch Intern Med 1981;141:926–930
131. Schimpff S. Intravenous sulfamethoxazole-trimethoprim plus ticarcillin as empiric antibiotic therapy for granulocytopenic patients. Arch Intern Med 1981;141:844–846
132. Issell B.F., Bodey G.P. Mezlocillin for treatment of infections in cancer patients. Antimicrob Agents Chemother 1980;17:1008–1013
133. Clough J.V., Farrell I.D., Wood M.J., Leyland M.J. Ceftazidime plus mezlocillin as initial antibiotic therapy in febrile neutropenic patients with haematological malignancy. J Antimicrob Chemother 1985;15: 353–363
134. Jones P., Rolston K., Fainstein V., Elting L., Bodey G.P. Aztreonam plus vancomycin (plus amikacin) vs. moxalactam plus ticarcillin for the empiric treatment of febrile episodes in neutropenic cancer patients. Rev Infect Dis 1985;7(suppl 4):S741–S746
135. de Pauw B., Williams K., de Neeff J., Bothof T., de Witte T., Holdrinet R., Haanen C. A randomized prospective study of ceftazidime versus ceftazidime plus fluclomacillin in the empiric treatment of febrile episodes in severely neutropenic patients. Antimicrob Agents Chemother 1985;28:824–828
136. Darbyshire P.J., Williamson P.J., Pedler S.J., Speller D.C., Mott M.G., Oakhill A. Ceftazidime in the treatment of febrile immunosuppressed children. J Antimicrob Chemother 1983;12(suppl A):357–360
137. Morgan G., Duerden B.I., Lilleyman J.S. Ceftazidime as a single agent in the management of children with fever and neutropenia. J Antimicrob Chemother 1983;12(suppl A):347–351
138. d’Oliveira J.J., Pereira M.E., Mateus L.M., Monteiro J.M., Parreira A.S., Soares A.D. Use of ceftazidime in febrile incidents in immunocompromised haematological patients. J Intern Med Res 1986;14:30–34
139. Bolivar R., Fainstein V., Elting L., Bodey G.P. Cefoperazone for the treatment of infections in patients with cancer. Rev Infect Dis 1983;5(suppl): SI 81–SI 87
140. Smith G.M., Leyland M.J., Farrell I.D., Geddes A.M. Preliminary evaluation of ciprofloxacin, a new 4-quinolone antibiotic in the treatment of febrile granulocytopenic patients. J Antimicrob Chemother 1986;18(suppl D):115–174
141. Beun G.D.M., Debrus-Palmans L.L., Daniels-Bosman M.S.M., Blijham G.H. Therapy with perfloxacin in febrile neutropenic patients [abstract]. Rev Infect Dis 1988;10(Suppl 1):S236
142. Bodey G.P., Alvarez M.E., Jones G.P., Rolston K.V., Steelhammer L., Fainstein V. Imipenem-cilastatin as initial therapy for febrile cancer patients. Antimicrob Agents Chemother 1986;30:211–214
143. Wade J.C., Standiford H.C., Drusano G.L., Johnson D.E., Moody M.R., Bustamanti C.l., Joshi J.H., de Jongh C., Schimpff S.C. Potential of im- ipenem as single-agent empiric antibiotic therapy of febrile neutropenic patients with cancer. Am J Med 1985;78:62–72
144. Bodey G.P., Grose W.F., Keating W.J. Use of trimethoprim-sulfamethoxazole for treatment of infections in patients with cancer. Rev Infect Dis 1982;4:579–585
145. Enno A., Catovsky D., Darrel J., Goldman J.M., Hows J., Gatton D.A.G. Co-trimoxazole for prevention of infection in acute leukemia. Lancet 1978;2:395–397
146. Gurwith M.J., Brunton J.L., Lank B.A., Harding G.K.M., Ronald A.R. A prospective controlled investigation of prophylactic trimethoprim/sulfamethoxazole in hospitalized granulocytopenic patients. Am J Med 1979;66:248–256
147. Gaya H., Glauser M., Klastersky J., Zinner S., Schimpff S.C., Tattersall M.H.N. Double-blind placebo-controlled trial of prophylactic trimethoprim and sulfamethoxazole for the prevention of infection in granulocytopenic patients [abstract 331]. In: Proceedings of the 20th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, 1980
148. Malarme M., Meunier-Carpentier F., Klastersky J. Vancomycin plus gentamicin and cotrimoxazole for prevention of infection in neutropenia cancer patients. Eur J Cancer Clin Oncol 1981;17:1315–1322
149. Sleijfer D.T., Mulder N.H., de Vries-Hospers H.G., Fidler V., Nieweg H.O., van der Waaj D., van Saene H.K.F. Infection prevention in granulocytopenic patients by selective decontamination of the digestive tract. Eur J Cancer 1980;16:859–869
150. Dekker A.W., Rozenberg-Arska M., Sixma J.J., Verhoef J. Prevention of infection by trimethoprim-sulfamethoxazole plus amphotericin B in patients with acute nonlymphocytic leukemia. Ann Intern Med 1981; 95:555–559
151. Wade J.C., Schimpff S.C., Hargadon M.T., Fortner C.L., Young V.M., Wier- nik P.H. A comparison of trimethoprim-sulfamethoxazole plus nystatin with gentamicin plus nystatin in the prevention of infections in acute leukemia. N Engl J Med 1981;304:1057–1062
152. Weiser B., Lange M., Fialk M.A., Singer C., Szatrowski T.H., Armstrong D. Prophylactic trimethoprim-sulfamethoxazole during consolidation chemotherapy for acute leukemia: A controlled trial. Ann Intern Med 1981;95:436–438
153. Calvo F., Marty M., Lepors J.S., Ferme C., Boiron M. Antibiotic prophylaxis against infections in acute leukemia. N Engl J Med 1981; 305:583–584
154. Preisler H.D., Early A., Hrymiuk W. Prevention of infection and bleeding in leukemia patients receiving intensive remission maintenance therapy. Med Pediatr Oncol 1981;9:511–521
155. Zinner S., Gaya H., Glauser M., Hann I., Klastersky J., Schimpff S., Tattersall M. Cotrimoxazole and reduction of risk of infection in neutropenic patients: A progress report [abstract 795]. In: Proceedings of the 21st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 1981
156. Gurwith M., Truog K., Hinthom E., Chien L. Trimethoprim-sulfamethoxazole and trimethoprim alone for prophylaxis of infection in granulocytopenic patients. Rev Infect Dis 1982;4:593–601
157. Watson J.G., Jameson B., Powles R.L., McElwain T.J., Lawson D.N., Judson I., Morgenstem G.R., Lumley H., Kay H.E.M. Co-trimoxazole veisus nonabsorbable antibiotics in acute leukemia. Lancet 1982;1:6–9
158. Starke I.D., Donnelly P., Catovsky D., Darrell J., Johnson S.A., Goldman J.M., Galton D.A.G. Co-trimoxazole alone for prevention of bacterial infection in patients with acute leukemia. Lancet 1982;1:5–6
159. Scaglione C., Tormena A.M., Pavlovsky S. Estudios controlados de profilaxis con cotrimoxasol en pacientes neutropenicos afebriles con hemopatias malignas. Sangre 1982;27:912–918
160. Pizzo P.A., Robichaud K.J., Edwards B.K., Schumaker C., Kramer B.S., Johnson A. Oral antibiotic prophylaxis in patients with cancer. A doubleblind randomized placebo-controlled trial. J Pediatr 1983;102:125–133
161. Gualtieri R.J., Donowitz G.R., Kaiser D.L., Hess C.E., Sande M.A. Doubleblind randomized study of prophylactic trimethoprim/sulfamethoxazole in granulocytopenic patients with hematologic malignancies. Am J Med 1983;74:934–940
162. Riben P.D., Louie T.J., Lank B.A., Kornachuk E., Gurwith M.J., Harding G.K., Ronald A.R. Reduction in mortality from gram-negative sepsis in neutropenic patients receiving trimethoprim/sulfamethoxazole therapy. Cancer 1983;51:1587–1592
163. Kauffman C.A., Liepman M.K., Bergman A.G., Mioduszewski J. Trimethoprim/sulfamethoxazole prophylaxis in neutropenic patients. Am J Med 1983;74:599–607
164. Wade J.C., de Jongh C.A., Newman K.A., Crowley J., Wiemik P.H., Schimpff S.C. Selective antimicrobial modulation as prophylaxis against infection during granulocytopenia: trimethoprim/sulfamethoxazole vs. nalidixic acid. J Infect Dis 1983:147:624–634
165. Inoue M., Arai S., Kamiya H., Sakurai M., Izawa T., Yamakawa T., Kamiya K., Nishimura Y., Kato T., Hiratani Y., Akatuka J., Hirotu T. The prophylactic effect of trimethoprim-sulfamethoxazole against infection among children with acute leukemia. Rinsho Ketsueki 1983:24: 26–33
166. Rozenberg-Arska M., Dekker A.W., Verhoef J. Colistin and trimethoprimsulfamethoxazole for the prevention of infection in patients with acute non-lymphocytic leukemia. Decrease in the emergence of resistant bacteria. Infection 1983;11:167–169
167. de Jongh C.A., Wade J.C., Finley R.S., Joshi J.H., Aisner J., Wiemik P.H., Schimpff S.C. Trimethoprim-sulfamethoxazole versus placebo: A double-blind comparison of infection prophylaxis in patients with small cell carcinoma of the lung. J Clin Oncol 1983;1:302–307
168. Estey E., Maksymiuk A., Smith T., Fainstein V., Keating M., McCredie K.B., Freireich E.J., Bodey G.P. Infection prophylaxis in acute leukemia: comparative effectiveness of sulfamethoxazole and trimethoprim, ketoconazole and a combination of the two. Arch Intern Med 1984;144:1562–1568
169. Hughes W.T., Patterson G. Post-sepsis prophylaxis in cancer patients. Cancer 1984;53:137–141
170. Henry S. Chemoprophylaxis of bacterial infections in granulocytopenic patients. Am J Med 1984;76:645–651
171. EORTC International Antimicrobial Therapy Project Group. Trimethoprim-sulfamethoxazole in the prevention of infection in neutropenic patients. J Infect Dis 1984;150:372–379
172. Lange B., Halpem S., Gale G., Kramer S. Trimethoprim-sulfamethoxazole and nystatin prophylaxis in children with acute lymphoblastic leukemia. Eur Paediatr Hematol Oncol 1984;1:231–238
173. Kovatch A.L., Wald E.R., Albo V.C., Prin W., Orlando S.J., Wollman M.R., Phebus C.K., Shapiro E.D. Oral trimethoprim/sulfamethoxazole for prevention of bacterial infection during the induction phase of cancer chemotherapy in children. Pediatrics 1985;76:754–758
174. Goorin A.M., Hershey B.J., Levin M.J., Siber G.R., Gelber R.D., Flynn K., Lew M., Beckett K., Blanding P., Sallan S.E. Use of trimethoprim- sulfamethoxazole to prevent bacterial infections in children with acute lymphoblastic leukemia. Pediatr Infect Dis J 1985;4:265–269
175. Van Eys J., Berry D.M., Crist W., Doering E.J., Fembach D.U., Pullen J., Shuster J. Effect of trimethoprim/sulfamethoxazole prophylaxis on outcome of childhood lymphocytic leukemia. Cancer 1987;59:15–23
176. Ward T.T., Ochi S., James K. Double-blind randomized trial of oral prophylactic TMP/SMZ for infection in acute leukemia [abstract 1204], In: Proceedings of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, 1988